- Home
- ARCT vs RCKT Comparison
ARCT vs RCKT Comparison
Compare ARCT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- RCKT
- Stock Information
- Founded
- ARCT 2013
- RCKT 1999
- Country
- ARCT United States
- RCKT United States
- Employees
- ARCT N/A
- RCKT N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- RCKT Health Care
- Exchange
- ARCT Nasdaq
- RCKT Nasdaq
- Market Cap
- ARCT 320.8M
- RCKT 328.6M
- IPO Year
- ARCT N/A
- RCKT N/A
- Fundamental
- Price
- ARCT $19.48
- RCKT $3.05
- Analyst Decision
- ARCT Strong Buy
- RCKT Buy
- Analyst Count
- ARCT 8
- RCKT 13
- Target Price
- ARCT $48.83
- RCKT $12.88
- AVG Volume (30 Days)
- ARCT 648.4K
- RCKT 2.5M
- Earning Date
- ARCT 08-11-2025
- RCKT 08-07-2025
- Dividend Yield
- ARCT N/A
- RCKT N/A
- EPS Growth
- ARCT N/A
- RCKT N/A
- EPS
- ARCT N/A
- RCKT N/A
- Revenue
- ARCT $122,122,000.00
- RCKT N/A
- Revenue This Year
- ARCT N/A
- RCKT N/A
- Revenue Next Year
- ARCT $37.73
- RCKT $591.46
- P/E Ratio
- ARCT N/A
- RCKT N/A
- Revenue Growth
- ARCT N/A
- RCKT N/A
- 52 Week Low
- ARCT $8.04
- RCKT $2.19
- 52 Week High
- ARCT $25.88
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- ARCT 75.39
- RCKT 49.19
- Support Level
- ARCT $11.27
- RCKT $2.83
- Resistance Level
- ARCT $19.99
- RCKT $3.22
- Average True Range (ATR)
- ARCT 1.31
- RCKT 0.17
- MACD
- ARCT 0.79
- RCKT 0.01
- Stochastic Oscillator
- ARCT 94.15
- RCKT 41.51
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.